Prof Ole De Backer (Rigshospitalet, Copenhagen, DK) provides an update from the GALILEO-4D trial, discussing the comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves.

What is the GALILEO-4D study and how is it related to the main GALILEO trial?
What is the design of the study and what endpoints were aimed for?
What were the outcomes of the GALILEO-4D investigation?
How should this research influence future antithrombotic post-TAVR research?

Filmed on site by Radcliffe Cardiology at AHA 2019.

Videographer: Tom Green & Dominic Woodruff

Prof Ole De Backer (Rigshospitalet, Copenhagen, DK) provides an update from the GALILEO-4D trial, discussing the comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves.

What is the GALILEO-4D study and how is it related to the main GALILEO trial?
What is the design of the study and what endpoints were aimed for?
What were the outcomes of the GALILEO-4D investigation?
How should this research influence future antithrombotic post-TAVR research?

Filmed on site by Radcliffe Cardiology at AHA 2019.

Videographer: Tom Green & Dominic Woodruff